ADPT President and COO Julie Rubinstein Sells $286K of Stock

Adaptive Biotechnologies Corporation President and COO Julie Rubinstein sold 11,881 shares of the company stock on October 19, 2026. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the transaction was executed at a price of $24.05 per share, for a total value of $285,738.05.

ADPT Adaptive Biotechnologies Corporation

$25.33 ▲ +59.21% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Julie Rubinstein's ADPT Trade

The shares were sold pursuant to a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Rubinstein directly owned 377,802 shares of Adaptive Biotechnologies stock, cutting her holdings by about 3.1%. The stock closed at $23.95 on the day of the trade.

Other Institutional Activity in Adaptive Biotechnologies

Other large funds have adjusted their positions in the company recently. Viking Global Investors, L.P. maintained its holdings, ending with 29,993,708 shares worth about $759,740,621. Shaw D.E. & Co., Inc. grew its holdings by 2,660,252 shares, ending with 4,625,859 shares worth about $117,173,008, a 135.3% increase. Westfield Capital Management Co LP reduced its stake by 1,168,845 shares, ending with 4,267,645 shares worth about $108,099,447, a 21.5% decrease.

Adaptive Biotechnologies Corporation Stock Holds Steady

The stock recently traded around $24.42, which is up about 2.0% from its closing price of $23.95 on the transaction date. Shares are trading below the 50-day moving average of $26.13 but remain above the 200-day moving average of $19.22.

Recent Earnings

The company posted trailing twelve month revenue of $308.08 million with an earnings per share of -$0.41. The next quarterly financial report is scheduled for November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

This transaction follows a series of planned sales by Rubinstein earlier in October, including trades on October 13, October 14, October 15, and October 16, 2026. Insider transactions of this nature are frequently executed under pre-scheduled trading guidelines to manage personal portfolios.

Analysts Set New Price Targets

Wall Street analysts maintain a positive outlook on the stock. BTIG maintains a buy rating with a $34.00 target, Goldman Sachs initiated coverage with a buy rating and a $35.00 target, Guggenheim maintains a buy rating with a $32.00 target, TD Cowen maintains a buy rating with a $32.00 target, and Morgan Stanley maintains an equal-weight rating with a $27.00 target. The consensus recommendation stands at a strong buy with a mean price target of $29.81.

About Adaptive Biotechnologies Corporation

The Seattle-based healthcare company operates a commercial-stage platform focused on immune medicine for diagnosing and treating various diseases. Its immunosequencing technology combines proprietary chemistry, computational biology, and machine learning to decode the adaptive immune system.

Bottom Line

Investors will look toward the upcoming earnings release on November 4, 2026, for further updates on financial performance and operational progress.